Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Thiamidol + Eucerin** refers to a combination of topical skincare products developed by Eucerin (a Beiersdorf brand) that contain Thiamidol as the principal active ingredient. Thiamidol (4-butylresorcinol) is a patented compound specifically developed and clinically proven to reduce hyperpigmentation by inhibiting the enzyme tyrosinase, the key enzyme involved in melanin (pigment) biosynthesis. By blocking tyrosinase, Thiamidol effectively reduces melanin production, gradually fading existing pigment spots and preventing their recurrence. Eucerin’s formulations are primarily aimed at treating conditions like melasma, age spots, post-inflammatory hyperpigmentation, and general skin tone irregularities. The combination of Eucerin’s topical technology (carriers such as serums, creams, and SPF products) and Thiamidol enables effective and well-tolerated treatment suitable for all skin types and tones. The Eucerin Thiamidol products show results in as early as two weeks, with significant improvement (up to 75% reduction in pigmentation) in 12 weeks. These products are regarded as both effective and gentle, with fewer side effects compared to commonly used agents like hydroquinone[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thiamidol + Eucerin.